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Summary Chronic obstructive pulmonary disease (COPD) is associated with an
increased load on the diaphragm. Chronic loading on skeletal muscles results in
metabolic changes and fiber-type shifts. Therefore, we investigated whether the
load on the human diaphragm imposed by COPD altered oxidative enzyme activity,
glycogenolytic enzyme activity and mitochondrial energy generating capacity and
efficiency. Biopsies of the diaphragm from COPD patients and control subjects wereee front matter & 2005
med.2005.09.029
s: COPD, chronic obstru
ity; TLC, total lung cap
hain; SDS–PAGE, sodium
C, functional residual c
I, complex III; C-IV, com
ing author. Tel.: + 31 24
ess: R.Dekhuijzen@longobtained and activities of L(+)3-hydroxyacylCoA-dehydrogenase (HADH, marker for
b-oxidation capacity) and phosphorylase (marker for glycogenolytic capacity) were
measured spectrophotometrically. Mitochondrial energy generating capacity was
measured by spectrophotometrical and radiochemical methods. Fiber-type distribu-
tion was determined electrophoretically. We found that HADH activity was increased
with increasing severity of COPD (P ¼ 0:05). No change in glycogenolytic enzyme
activity was observed. The activity of the mitochondrial respiratory chain complexes
III and IV and oxidation of pyruvate was increased with increasing airflow
obstruction. These results suggest that in COPD the diaphragm adapts to a higher
workload by increasing the oxidative capacity and mitochondrial function.
& 2005 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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COPD
(n ¼ 19)
Non-COPD
(n ¼ 12)
Age (years) 6172 6072
BMI 2671 2571
FEV1 (l) 1.9570.18** 3.2070.17
FEV1 % predicted 6475** 10374
FEV1/VC 5073** 7771
TLC % predicted 10076 10073
KCO 1.0370.06* 1.3070.04
KCO % predicted 6874* 8773
FRC % predicted 109710 86710
Values are means7SEM. FEV1, forced expiratory volume in
1 s; VC, vital capacity; TLC, total lung capacity; KCO,
diffusion coefficient; FRC, functional residual capacity.
Po0:05 and Po0:001 between COPD and non-COPD
patients in the same group.In patients with chronic obstructive pulmonary
disease (COPD), adaptations in the diaphragm
occur as a result of increased workload. These
adaptations include a shift from type II fibers
towards type I fibers,1,2 which is most pronounced
in patients with very severe COPD.1 Levine et al.3
hypothesized that the diaphragms of severe COPD
patients are undergoing endurance-exercise train-
ing. However, endurance training programs that
elicit these effects, consist normally of training
sessions at appropriate intensity which are sepa-
rated by rest. In the diaphragm, this rest is rather
impossible. Therefore, the diaphragm in COPD
might come in a state of ‘‘overtraining’’, with all
the deleterious consequences. In limb muscles,
endurance training elicits a hypertrophy of type I
fibers,4 an increase in oxidative capacity,4–7 and an
increase in capillarization.4 Given the fact that the
workload is increased in COPD diaphragm, similar
adaptations as elicited by exercise training may
occur, for example changes in activity of oxidative
enzymes and enzymes involved in anaerobic meta-
bolism. Indeed, Levine et al.3 found an increase in
succinate dehydrogenase (SDH) activity in dia-
phragm fibers of COPD patients versus control
subjects. Sanchez et al.8 reported a decrease of
glycolytic enzyme activity (lactate dehydrogenase
(LDH) and hexokinase) in the diaphragm of patients
with moderate COPD.
In addition to an upregulation in oxidative
enzyme activity, changes in mitochondrial function
may occur. Indeed, Ribera et al.9 showed an
increased mitochondrial respiration and efficiency
in diaphragm of COPD patients. Besides a change in
function, also an increase in mitochondrial density
has been reported in COPD diaphragm.10 However,
it is not known which parts of the mitochondrial
energy generating system are changed in the
diaphragm of COPD patients.
These metabolic enzyme activities and mito-
chondrial function are in part related to fiber type,
since type I fibers contain more oxidative capacity
whereas type II fibers contain more glycolytic
capacity.7 Besides, training can also increase
oxidative enzyme activities without major shifts
in fiber types.11
In this study, we tested the following hypotheses:
With increasing severity of COPD: (1) the oxidative
enzyme activity increases, (2) the glycogenolytic
enzyme activity decreases, and (3) the mitochon-
drial energy generating capacity is enhanced.
Furthermore, we determined to what extent the
changes in enzyme activities paralleled the shift in
fiber type with increasing severity of COPD. To testglycogenolytic enzyme activity, mitochondrial en-
ergy generating capacity and fiber-type shifts in the
diaphragm of patients with COPD.Methods
Subjects
Nineteen patients with mild to severe COPD (mean
forced expiratory volume in 1 s (FEV1) ¼ 64 (range
18–114)% predicted; FEV1/vital capacity (VC) ¼ 50
(range 18–61)%) and seven male non-COPD patients
(mean FEV1 ¼ 102 (range 81–117)% predicted;
FEV1/VC ¼ 77 (range 70–83)%), who were under-
going thoracic surgery for a malign T1 lung tumor
participated in this study. General characteristics
and pulmonary function data are shown in Table 1.
Informed consent for diaphragm biopsies was
obtained from each of the subjects, and the study
was approved by the ethical committee of our
hospital.Biopsies
For measurements of enzyme activity, biopsies of
the anterior costal diaphragm were obtained,
directly frozen in liquid nitrogen, and stored at
–80 1C until being used. For measurements of
mitochondrial function, fresh biopsies were put
immediately in ice-cold SETH buffer (0.25M su-
crose, 2mM EDTA, 10mM Tris, 5 104 U heparin, pH
7.4) and delivered within 1 h in the laboratory.
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Spectrophotometric analyses were performed to
determine the activity of L(+)3-hydroxyacylCoA-dehy-
drogenase (HADH, oxidative enzyme [n ¼ 15]) and
phosphorylase (glycogenolytic enzyme [n ¼ 14]).
The procedures to determine biochemical activities
of the oxidative and glycogenolytic enzymes were
performed as described previously.12 Briefly, fresh
frozen biopsies were thawed in ice-cold SET buffer
(0.25M sucrose, 2mM EDTA, 10mM Tris, pH 7.4). In
this buffer, muscle homogenates (5% w/v) were
prepared using a Potter–Elvehjem glass–teflon
homogenizer. Total phosphorylase (a+b) activity
was assayed at 37 1C and expressed as mM NADPH
formed min1 g wet tissue. HADH activity, assessed
at 50 mmol acetoacyl-CoA at 37 1C, was expressed
in nmol NADH oxidized min1 g wet tissue. All
assays for metabolic enzymes were performed in
duplicate.Mitochondrial energy generating capacity
Equipment and Materials
[1-14C] Pyruvic acid, sodium salt (0.4–1.1 GBq/
mmol) was obtained from ICN. Pyruvic acid, sodium
salt, L-malic acid, creatine, sodium-m-arsenite,
atractyloside, potassium salt and p1,p5-di(adeno-
sine-50) pentaphosphate (Ap5A) were obtained from
Sigma (St. Louis, MO., USA). Adenosine-50-dipho-
sphate disodium salt (ADP), hexokinase, glucose-6-
phosphate dehydrogenase, L-lactate-dehydrogen-
ase and NADH were obtained from Roche (Ont.,
Canada). All chemicals were of the highest purity
commercially available. Glass incubation vials of
20ml capacity, with injection caps and rubber
septums, hydroxide or hyamine 10-X (hyamine) and
Insta Fluor were obtained from Packard Becker BV
(Groningen, The Netherlands). All solutions were
prepared with ultra-pure water from a Milli-Qplus
water purification system.Homogenization procedure of muscle tissue
Muscle tissue was washed with fresh ice-cold SETH,
and fat and connective tissue were disconnected.
Tissue was cut in very small pieces of about
0.1 0.1mm with help of a Sorvall TC2 tissue
chopper with razor blade. Tissue was homogenized
in fresh ice-cold SETH buffer (5–10% w/v) with a
Potter–Elvehjem tissue homogenizer according to
Fischer et al.13 Some 100 ml samples of the crude
homogenate were frozen immediately in liquid
nitrogen and kept at 80 1C for measuring protein
content, cytochrome c oxidase and citrate synthase
(CS). The rest of the crude homogenate wascentrifuged for 10min at 2 1C at 600g. The 600g
supernatant was frozen in 100 ml aliquots in liquid
nitrogen and kept at 80 1C for measuring protein
content, CS activity and activities of respiratory
chain enzymes. CS activity was measured according
to Srere14 with minor modifications. Protein concen-
tration was measured according to Lowry et al.15 with
minor modifications.Incubations
Incubations were performed in a shaking water
bath at 37 1C in 20ml glass incubation vials closed
with injection caps and rubber septums. In the
incubations for measuring oxidation rates for 14C-
labelled substrates, the glass vial contained a small
plastic tube inside a plastic cylinder, the tube
containing 0.2ml hyamine. Incubation volume was
0.5ml and the incubation time was 20min. Incuba-
tions were carried out in 30mM potassium phos-
phate, 75mM potassium chloride, 8mM Tris, 1.6mM
EDTA, 5mM MgCl2, 0.2mM Ap5A and where indi-
cated 2.0mM ADP, 20mM creatine, 1mM sodium
pyruvate, 1mM malic acid, 78 kBq [1-14C] sodium
pyruvate and 2mM sodium arsenite. Only incuba-
tions in the presence of ADP also contained
creatine. In the incubations for measuring ATP
production rates, radioactive substrates were
omitted. After 20min the incubations were stopped
by adding 0.2ml 3M perchloric acid through the
rubber septum to the incubation mixture with help
of a hypodermic syringe. Incubations for measuring
ATP production rates were stopped by opening the
vial and adding the same amount of perchloric acid
with an Eppendorf pipette. Incubations were
allowed to stand for 1 h in ice for fully trapping
14CO2 into the hyamine. After 1 h the tubes
containing the hyamine were taken out, mixed
with 5ml Insta Fluor and counted in a Wallac 1400
Liquid Scintillation Counter. Incubations for mea-
suring ATP production rates were allowed to stand
in ice for 15min and after that the incubation
mixtures were centrifuged for 5min, 14,000g, at
2 1C in an Eppendorf 5402 centrifuge. 0.5ml of the
supernatant were neutralized by adding 0.6ml ice
cold 1M KHCO3 under thoroughly stirring on a
vortex mixer. The mixtures were allowed to stand
in ice for 15min and were frozen at 20 1C.
Incubations for determination of the activity of
complex I (C-I) and succinate cytochrome c
oxidoreductase (SCC) were performed according
to Fischer16,17 with minor modifications. Incuba-
tions for determination of complex III (C-III) and
complex IV (C-IV) activity were performed accord-
ing to Bentlage et al.18 and Cooperstein and
Lazarow,19 respectively.
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Neutralized incubation mixtures were thawed and
put on ice for 5min. The mixtures were centrifuged
at 2 1C in an Eppendorf 5402 centrifuge. ATP and
creatine phosphate were measured spectrophoto-
metrically at 340 nm and 25 1C. A total of 0.4ml of
supernatant were incubated in a semi-micro-acryl
cuvette in a total volume of 1.0ml, containing
0.3M triethanolamine, 3.3mM NADP, 1.6mM ADP,
5.3mM MgSO4 and 33mM glucose, pH 7.5.
Absorbance (E0) was measured and 5 ml of a
mixture of hexokinase (6 U) and glucose-6-phos-
phate dehydrogenase (1.75 U) were added and
mixed. After the absorbance had become constant,
absorbance was measured (E1) and 5 ml creatine
kinase (1 U) were added and mixed. After absor-
bance had become constant again, absorbance (E2)
was measured. The increase in absorbance E1–E0
was used to calculate ATP content. The increase in
absorbance E2–E1 was used to calculate creatine
phosphate content. An e340 for NADPH of
6.22mmol1 cm1 was used.
Fiber-type determination
A part of the biopsy was stored in 80 1C to
determine myosin heavy chain (MHC) composition.
Sections of this sample that were 10-mm-thick were
dissolved in sodium dodecyl sulphate (SDS) sample
buffer and boiled for 2min. The MHC composition
was determined by SDS polyacrylamide (7%) gel
electrophoresis (SDS–PAGE). Electrophoresis was
performed at 100 V for 27 h with Tris–glycine
electrode buffer at 15 1C (Protean II xi, Bio-Rad,
USA). Gels were then silver stained. The gels were
scanned with an imaging densitometer and optical
densities (OD) of different MHC bands were
quantified with GeneTools software (Syngene, UK).
Statistical analysis
Data were analyzed with SPSS for Windows, version
12.0.1 (SPSS, Chicago, IL). A t test was used to
compare results between groups. To establish theTable 2 Enzyme activities and myosin heavy chain distr
COPD (n ¼ 11)
Phosphorylase activity (U/g) 0.2770.04
HADH activity (U/g) 7.2470.83
% MHC type I 4172
% MHC type Iia 3972
% MHC type Iix 2372
Values are means7SEM. HADH, L(+)3-hydroxyacylCoA-dehydrogenarelationship between the metabolic capacity and
lung function parameters and between the meta-
bolic capacity, mitochondrial function and MHC
composition, Pearson correlation was determined.
Significance was set at the 0.05 level.Results
Patients characteristics
The COPD patients did not differ significantly from
the control subjects with respect to age or body
mass index (BMI) (Table 1). Clearly, the COPD
subjects showed lower values with respect to the
FEV1, FEV1 percentage of predicted, the ratio of
the FEV1 to forced VC, diffusion coefficient (KCO)
and KCO percentage of predicted. The COPD
patients in the mitochondrial group had lower
values with respect to FEV1 percentage of pre-
dicted and the ratio of FEV1 to forced VC.
Metabolic changes
The activities of HADH and phosphorylase are
presented in Table 2. There was no significant
difference in HADH activity between the COPD and
non-COPD group (P ¼ 0:19). However, there was a
significant inverse correlation between HADH ac-
tivity and FEV1 % predicted (r ¼ 0:51, P ¼ 0:05) in
the COPD group (Fig. 1A). Between the COPD and
non-COPD group there was no significant difference
regarding phosphorylase activity (P ¼ 0:26). No
significant correlation was found between phos-
phorylase activity and FEV1 % predicted (r ¼ 0:54,
P ¼ 0:13) in the COPD group (Fig. 1B).
Mitochondrial function
CS activity was not different between the COPD
patients and non-COPD patients (P ¼ 0:47), nor was
there any correlation of CS activity with a
pulmonary function parameter. Therefore, it isibution.
Non-COPD (n ¼ 7) P-value
0.2170.03 0.26
4.9570.87 0.09
3773 0.34
3374 0.11
2674 0.47
se; MHC, myosin heavy chain.
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mitochondrial content. There were no significant
differences between the COPD group and the non-
COPD group regarding any of the mitochondrialTable 3 Mitochondrial parameters.
COP
[1-14C] Pyruvate+malate (nmol/hmUCS1) 2.8
ATP production (nmol/hmUCS1) 29.0
ATP/pyruvate 9.7
ADP stimulation 4.6
C-I (mU/UCS) 10
C-III (mU/UCS) 274
SCC (mU/UCS) 57
C-IV (mU/UCS) 216
CS (mU/ml) 15
Values are means7SEM. ADP, adenosine diphosphate; ATP adenosin
and [1-14C] Pyruvate+malate; ADP stimulation, ADP stimulation of
complex; SCC, succinate cytochrome c oxidoreductase; C-IV, cyto
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Figure 1 Relationship between FEV1 and activities of the
enzymes phosphorylase (A), and L(+)3-hydroxyacylCoA-
dehydrogenase (HADH) (B) within the COPD group. An
inverse correlation was found between FEV1 and HADH
(r ¼ 0:51, P ¼ 0:05). No significant correlation was
found between FEV1 and phosphorylase (r ¼ 0:54,
P ¼ 0:13).parameters (Table 3). However, in the COPD group
there were significant correlations between several
lung function parameters and mitochondrial para-
meters, such as oxidation of [1-14C] pyruvate+ma-
late and total lung capacity (TLC) % predicted
(r ¼ 0:92, P ¼ 0:01) (Fig. 2A). In addition, signifi-
cant correlations were observed between oxidation
of [1-14C] pyruvate+malate and VC % pred
(r ¼ 0:806, P ¼ 0:04), functional residual capacity
(FRC) % pred (r ¼ 0:913, P ¼ 0:01) and KCO
(r ¼ 0:836, P ¼ 0:04). Furthermore, significant
correlations were found between C-III activity and
TLC % predicted (r ¼ 0:80, P ¼ 0:03) (Fig. 2B) and
FRC % predicted (r ¼ 0:76, P ¼ 0:05). Besides,
significant correlations were observed between C-
IV activity and KCO % predicted (r ¼ 0:94, Po0:01)
(Fig. 2C), KCO (r ¼ 0:847, P ¼ 0:01) and VC %
predicted (r ¼ 0:848, P ¼ 0:02).MHC composition
The distribution of the MHC isoforms is presented in
Table 2. There was no difference in percentage of
the different MHC types between COPD and non-
COPD diaphragm (P ¼ 0:34). No significant correla-
tion was found between any of the pulmonary
function parameters and relative amount of the
different MHC isoforms in the COPD group.Discussion
To our knowledge, this is the first investigation to
examine the effects of COPD on bio-energetic
enzyme activities combined with mitochondrial
capacity and fiber-type changes. The principal
findings of this study are that between COPD and
non-COPD patients, there were no differences inD (n ¼ 9) Non-COPD (n ¼ 4) P-value
770.35 2.7570.61 0.86
574.92 24.2874.82 0.51
070.43 9.0070.56 0.34
470.24 4.0470.34 0.17
079 8179 0.18
97163 27877168 0.88
7754 554728 0.78
27187 18907149 0.33
2711 136744 0.47
e triphosphate; ATP/pyruvate, ratio between ATP production
the pyruvate oxidation; C-I, complex I; C-III, cytochrome b-c1
chrome c oxidase (COX); CS, citrate synthase.
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Figure 2 Relationship between several pulmonary func-
tion parameters and mitochondrial parameters. A sig-
nificant relationship was found between TLC % predicted
and pyruvate+malate+ADP (r ¼ 0:92, P ¼ 0:01) (A), TLC %
predicted and CIII (r ¼ 0:80, P ¼ 0:03) (B) and between
KCO % predicted and CIV (r ¼ 0:94, Po0:01) (C).
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sition and mitochondrial energy generating capa-
city, but with increasing airflow obstruction (1) the
activity of HADH was increased, (2) the activity of
phosphorylase was not changed and (3) the activ-
ities of C-III and C-IV of the mitochondrial respira-
tory chain were increased, as well as the oxidation
of pyruvate in the presence of malate. Thedistribution of MHC isoforms was not different,
but tended to shift towards the oxidative isoforms
in COPD diaphragm.
Several metabolic changes can occur in the
diaphragm of COPD patients. First, due to over-
loading, a compensatory mitochondrial energy gen-
erating mechanism in energy production from the
mitochondrial respiratory chain can be induced.
Ribera et al.9 demonstrated that mitochondrial
oxidative capacity in the diaphragm of COPD patients
is increased. They found an increase in the maximal
respiration of mitochondria and an improvement in
the coupling of oxidation to phosphorylation in the
diaphragm of COPD patients. The latter finding
suggests an increased efficiency of mitochondrial
ATP production.9 In the present study we did not find
such an increased efficiency, as reflected by the ATP/
pyruvate ratio and ADP stimulation ratio. This
discrepancy in the findings could be due to the fact
that the patients in the study of Ribera et al.9 had
more severe airflow obstruction, namely FEV1 64% of
predicted in our study versus FEV1 33% of predicted
in the study of Ribera et al.9
In contrast to the unchanged mitochondrial
efficiency, we did find an increase in C-III and C-IV
activity and an increase in [1-14C] pyruvate+malate
oxidation rate with increasing severity of airflow
obstruction, suggesting an adaptive response to
increased loading. Sauleda et al.20 found an
increase of C-IV activity in the quadriceps femoris
of COPD patients, which was inversely related to
the arterial PO2 value. We postulate that the
increase in C-IV activity (and perhaps also other
parts of the mitochondrial respiratory chain) might
be related to chronic hypoxemia, which could
affect the diaphragm. The increase in [1-14C]
pyruvate+malate oxidation suggests an increase in
the function of the whole mitochondrial energy
generating capacity in diaphragm of COPD patients.
The finding that there was no difference in
mitochondrial function in direct comparison be-
tween COPD and non-COPD diaphragm could be due
to the low number of patients.
A second metabolic alteration which can occur in
the diaphragm of COPD patients, is an increase in
oxidative enzyme activity. Indeed, we found in this
study an increase in HADH activity with increasing
severity of COPD. Levine et al.3,21 reported an
increase in activity of the mitochondrial enzyme
SDH in patients with COPD. Tikunov et al.22 found
increased activities of HADH and CS in patients with
chronic heart failure, a condition which elicits
changes in the diaphragm which are comparable
with the changes found in COPD.
A third alteration which can occur is a decrease in
glycogenolytic enzyme activity, due to a shift
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occurring in COPD.1 However, in this study we did
not find a change in glycogenolytic enzyme activity
in COPD. After exercise training, Noble and Ianuzzo7
also found no significant changes in phosphorylase
activity in skeletal muscle of healthy rats. With the
exception of hexokinase, which behaves similarly to
the majority of mitochondrial enzymes, most
glycolytic enzymes do not change markedly in
response to endurance exercise in animals. In
slow-twitch muscle, endurance training may under
certain conditions result in a slightly increased
glycolytic potential.23 Endurance training does not
alter diaphragmatic glycolytic capacity.24,25 Baldwin
et al.23 and Gollnick et al.26 found that endurance
training appears to result in rather minor changes in
glycolytic enzyme activity in skeletal muscle. These
observations are in accordance with the results
found in the present study. However, Sanchez et al.8
reported a decrease of glycolytic enzyme activity
(LDH and hexokinase) in the diaphragm of moderate
COPD patients. The latter study did not show an
increase in oxidative enzyme activity in the dia-
phragm of COPD patients, possibly because the load
on the diaphragm in their patients was different
from ours. Besides, the low number of patients
might have contributed to the fact that we found no
significant difference in glygenocolytic activity.
We found no relationship between COPD and MHC
type I content in the diaphragm. This is in contrast
to the findings by Levine et al.1 and Mercadier et
al.2 who found an increase in percentage type I
MHC in COPD patients compared to controls. In our
study the COPD group showed a tendency to an
increase in percentage types I and IIa MHC and a
decrease in % type IIx MHC compared to the non-
COPD group. Possible explanations for this discre-
pancy could be less severe airflow obstruction in
our patients, namely FEV1 64% of predicted in our
study versus FEV1 33% of predicted in the study of
Levine et al.1
In conclusion, this study shows that with increas-
ing severity of COPD (1) the activity of oxidative
enzymes is increased, (2) the glycogenolytic activ-
ity is not changed and (3) the mitochondrial
capacity is increased. The distribution of MHC
isoforms tended to shift towards the oxidative
isoforms in COPD diaphragm. These alterations may
help the diaphragm dealing with a higher workload
associated with increased airflow limitation.Acknowledgements
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